var data={"title":"Famotidine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Famotidine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6179?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=famotidine-drug-information\" class=\"drug drug_general\">see &quot;Famotidine: Drug information&quot;</a> and <a href=\"topic.htm?path=famotidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Famotidine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169927\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Acid Reducer Maximum Strength [OTC];</li>\n      <li>Acid Reducer [OTC];</li>\n      <li>Heartburn Relief Max St [OTC];</li>\n      <li>Heartburn Relief [OTC];</li>\n      <li>Pepcid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169928\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Acid Control;</li>\n      <li>Apo-Famotidine;</li>\n      <li>Famotidine Omega;</li>\n      <li>Maximum Strength Pepcid AC;</li>\n      <li>Mylan-Famotidine;</li>\n      <li>Pepcid AC;</li>\n      <li>Pepcid Complete;</li>\n      <li>Peptic guard;</li>\n      <li>Teva-Famotidine;</li>\n      <li>Ulcidine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058659\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Histamine H<sub>2</sub> Antagonist</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442486\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastric acid suppression, GERD:</b> Oral: Initial: 0.5 mg/kg/dose once daily; if not effective, may increase to 1 mg/kg/dose once daily; in the trial, the minimum GA for inclusion was &ge;32 weeks and no minimum PNA inclusion criteria; the youngest patient reported to receive the higher 1 mg/kg/dose was 1.3 months PNA (median: 3.7 months; range: 1.3 to 10.5 months) (Orenstein 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stress ulcer prophylaxis, gastric acid suppression:</b> Limited data available: IV: 0.25 to 0.5 mg/kg/dose once daily has been used; some data have suggested that the lower dose of 0.25 mg/kg may have a less favorable pharmacodynamics profile (eg, duration of gastric pH &gt;4) than the higher 0.5 mg/kg dosage (James 1998; Wenning 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058653\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=famotidine-drug-information\" class=\"drug drug_general\">see &quot;Famotidine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GERD, esophagitis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 1 to &lt;3 months:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 0.5 mg/kg/dose once daily for up to 8 weeks; if not effective after 2 weeks, increasing to 1 mg/kg/dose once daily has been suggested (Orenstein 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Limited data available: 0.25 mg/kg/dose once daily; dosing based on a pharmacokinetic study which included seven patients &lt;3 months who received IV famotidine (Wenning 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 0.5 mg/kg/dose twice daily for up to 8 weeks if not effective after 2 weeks, increasing to 1 mg/kg/dose twice daily has been suggested (Orenstein 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Limited data available: 0.25 mg/kg/dose twice daily; dosing based on a pharmacokinetic study which include 11 patients &gt;3 to 12 months who received IV famotidine (Wenning 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &le;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Initial: 0.5 mg/kg/dose twice daily (maximum dose: 40 mg/dose); doses up to 1 mg/kg/dose twice daily have been reported</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Initial: 0.25 mg/kg/dose every 12 hours (maximum dose: 20 mg/dose); doses up to 0.5 mg/kg/dose every 12 hours have been reported</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 20 mg twice daily for up to 6 weeks; for esophagitis and accompanying symptoms due to GERD, may use 20 to 40 mg twice daily for up to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heartburn, acid indigestion, or sour stomach</b> (OTC labeling): Children &ge;12 years and Adolescents: Oral: 10 to 20 mg every 12 hours; dose may be taken 15 to 60 minutes before eating foods known to cause heartburn; maximum daily dose: 2 tablets/<b>day</b> (20 to 40 mg dependent upon OTC product)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pathological hypersecretory conditions (eg, Zollinger-Ellison):</b> Adolescents &ge;17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Initial: 20 mg every 6 hours, may increase up to 160 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peptic ulcer disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &le;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 0.5 mg/kg/<b>day</b> once daily at bedtime or divided twice daily (maximum daily dose: 40 mg/<b>day</b>); doses up to 1 mg/kg/<b>day</b> have been used</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Initial: 0.25 mg/kg/dose every 12 hours (maximum dose: 20 mg/dose); doses up to 0.5 mg/kg/dose every 12 hours have been reported</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duodenal ulcer: Acute therapy: 40 mg once daily at bedtime (or 20 mg twice daily) for 4 to 8 weeks; maintenance therapy: 20 mg once daily at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Gastric ulcer: Acute therapy: 40 mg once daily at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Stress ulcer prophylaxis, gastric acid suppression:</b> Limited data available: Infants, Children, and Adolescents: IV: 1 to 2 mg/kg/<b>day</b> in divided doses every 8 to 12 hours; maximum daily dose: 40 mg/<b>day </b>(Aanpreung 1998; ASHP 1999; Behrens 1994; Kraus 1990; Treem 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Duodenal ulcer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Acute therapy: 40 mg once daily at bedtime (or 20 mg twice daily) for 4 to 8 weeks; maintenance therapy: 20 mg once daily at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Esophagitis and accompanying symptoms due to GERD:</b></p>\n    <p style=\"text-indent:0em;margin-left:4em;\">Oral: 20 mg or 40 mg twice daily for up to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastric ulcer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Acute therapy: 40 mg once daily at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GERD:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 20 mg twice daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heartburn, indigestion, sour stomach:</b> OTC labeling: Oral: 10 to 20 mg every 12 hours; maximum dose: 40 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pathological hypersecretory conditions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Initial: 20 mg every 6 hours, may increase in increments up to 160 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no specific dosage adjustments provided in the manufacturer's labeling; however, decreased doses or extended dosing intervals are recommended in patients with moderate to severe renal impairment; some have suggested the following (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 0.5 to 1 mg/kg/day divided every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 0.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 0.25 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 0.125 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: 0.125 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 0.125 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 0.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;50 mL/minute: No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;50 mL/minute: Manufacturer recommendation: Administer 50% of dose or increase the dosing interval to every 36 to 48 hours (to limit potential CNS adverse effects)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169901\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg (50 mL); 20 mg/2 mL (2 mL); 40 mg/4 mL (4 mL); 200 mg/20 mL (20 mL); 500 mg/50 mL (50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepcid: 40 mg/5 mL (50 mL) [contains methylparaben sodium, propylparaben sodium, sodium benzoate; cherry banana mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg/5 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acid Reducer: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acid Reducer Maximum Strength: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heartburn Relief: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heartburn Relief Max St: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepcid: 20 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepcid: 20 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepcid: 40 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepcid: 40 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169887\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058663\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May administer with antacids. May be taken without regard to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension: Shake vigorously for 10 to 15 seconds prior to each use</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet (OTC): Do not chew; dose may be taken 10 to 60 minutes before eating food or drinking beverages known to cause heartburn</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: May be administered at a rate of &le;10 mg/minute over at least 2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion: Infuse over 15 to 30 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169921\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Powder for oral suspension: Prior to reconstitution, store at 25&deg;C (77&deg;F). Reconstituted oral suspension is stable for 30 days at room temperature; do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Store at room temperature. Protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution for injection: Prior to use, store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). If solution freezes, allow to solubilize at room temperature. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: Following preparation, solutions for IV push should be used immediately, or may be stored in refrigerator and used within 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infusion: Following dilution in D5W, D10W, NS or LR, may be stored for up to 48 hours under refrigeration; however, solutions for infusion have been found to be physically and chemically stable for 7 days at room temperature (maintains at least 90% of initial potency).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution for injection, premixed bags: Store at 25&deg;C (77&deg;F); avoid excessive heat.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058662\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prescription products: Short-term treatment for gastroesophageal reflux disease (FDA approved in all ages); short-term treatment of active duodenal ulcer and maintenance therapy after healing of active ulcer (FDA approved in ages &ge;1 year and adults); short-term treatment of active benign gastric ulcer (FDA approved in ages &ge;1 year and adults); treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas) (FDA approved in ages &ge;17 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">OTC products: Relief of heartburn, acid indigestion, and sour stomach (FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Has also been used for symptomatic relief in gastritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Short-term therapy and treatment for gastroesophageal reflux disease, duodenal ulcer, and active benign gastric ulcer until oral famotidine therapy can be initiated (FDA approved in ages 1 to 16 years and adults); treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas) until oral famotidine therapy can be initiated (FDA approved in ages &ge;17 years and adults); has also been used for stress ulcer prophylaxis and gastric acid suppression in critically ill patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7305905\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Famotidine may be confused with FLUoxetine, furosemide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169983\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation (&lt;1 year of age), dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, diarrhea, necrotizing enterocolitis (very low birth weight neonates; Guillet 2006), vomiting (&lt;1 year of age)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal distress, acne vulgaris, agranulocytosis, alopecia, anaphylaxis, angioedema, anorexia, anxiety, arthralgia, atrioventricular block, bronchospasm, cardiac arrhythmia, cholestatic jaundice, confusion, conjunctival injection, decreased libido, depression, drowsiness, dysgeusia, facial edema, fatigue, fever, flushing, hallucination, hepatitis, hypersensitivity reaction, increased liver enzymes, injection site reaction, insomnia, interstitial pneumonitis, leukopenia, muscle cramps, nausea, palpitations, pancytopenia, paresthesia, prolonged Q-T interval on ECG, pruritus, rhabdomyolysis, seizure, skin rash, Stevens-Johnson syndrome, thrombocytopenia, tinnitus, torsades de pointes, toxic epidermal necrolysis, urticaria, weakness, xeroderma, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169907\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to famotidine, other H<sub>2</sub> antagonists, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food, vomiting with blood, or bloody or black stools; allergic to other acid reducers; renal impairment; coadministration with other acid reducers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169891\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects.</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ECG changes: Prolonged QT interval has been reported in patients with renal dysfunction. The FDA has received reports of torsades de pointes occurring with famotidine (Poluzzi 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12</sub> deficiency: Prolonged treatment (&ge;2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment (CrCl &lt;50 mL/minute); dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; OTC labeling: When used for self-medication (OTC), notify health care provider before use if any of the following are present: Frequent chest pain; frequent wheezing particularly with heartburn; nausea/vomiting; unexplained weight loss; stomach pain; heartburn &gt;3 months; heartburn with light-headedness, sweating, or dizziness; chest pain or shoulder pain with shortness of breath; sweating; pain that spreads to arms, neck, or shoulders; light-headedness. Discontinue use and notify health care provider if heartburn continues or worsens, or if use is required &gt;14 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820029\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H<sub>2</sub> receptor antagonists; however, a causal relationship with ranitidine has not been demonstrated. A cohort analysis including over 11,000 neonates reported an association of H<sub>2</sub> blocker use and an increased incidence of NEC in VLBW neonates (Guillet 2006). An approximate sixfold increase in mortality, NEC, and infection (ie, sepsis, pneumonia, UTI) was reported in patients receiving ranitidine in a cohort analysis of 274 VLBW neonates (Terrin 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299312\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169896\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13295&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib.  Management: To minimize the potential for a significant interaction, separate administration of these agents by giving acalabrutinib 2 hours before ingestion of a histamine-2 receptor antagonist.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or after administration of a histamine H2-antagonist, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Histamine H2 Receptor Antagonists may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a non-diet cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Histamine H2 Receptor Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib.  Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of histamine H2-antagonists in combination with pazopanib.  Strategies to minimize the expected interaction between these agents (eg, dose separation) have not been investigated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use of oral suspension with H2-antagonists whenever possible. Monitor patients closely for decreased antifungal effects if this combination is used. Delayed-release posaconazole tablets may be less likely to interact.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Histamine H2 Receptor Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169924\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169898\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169910\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Famotidine crosses the placenta (Wang 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, renal clearance of famotidine may be increased (Wang 2011). Histamine H<sub>2</sub> antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD) during pregnancy. Agents other than famotidine may be preferred for initial therapy (Richter 2005; van der Woude 2014). Histamine H<sub>2</sub> antagonists may be used for aspiration prophylaxis prior to cesarean delivery (ASA 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50456256\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, gastric pH, occult blood with GI bleeding; renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169890\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitive inhibition of histamine at H<sub>2</sub> receptors of the gastric parietal cells, which inhibits gastric acid secretion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169906\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Antisecretory effect: Oral: Within 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Antisecretory effect: Oral: Within 1 to 3 hours (dose-dependent); IV: Within 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Antisecretory effect: IV, Oral: 10 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Incompletely absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 0 to 3 months of age: 1.4 &plusmn; 0.4 L/kg to 1.8 &plusmn; 0.3 L/kg; &gt;3 to 12 months: 2.3 &plusmn; 0.7 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;11 years of age: 2.07 &plusmn; 1.49 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 11 to 15 years of age: 1.5 &plusmn; 0.4 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 1.3 &plusmn; 0.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 15% to 20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: 30% to 35%; minimal first-pass metabolism; forms one metabolite (S-oxide)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 40% to 45%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 0 to 3 months of age: 8.1 &plusmn; 3.5 hours to 10.5 &plusmn; 5.4 hours; &gt;3 to 12 months: 4.5 &plusmn; 1.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;11 years of age: 3.38 &plusmn; 2.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 11 to 15 years of age: 2.3 &plusmn; 0.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2.5 to 3.5 hours; prolonged with renal impairment; Oliguria: &gt;20 hours; Anuria: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: ~1 to 3 hours; orally disintegrating tablet: 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (25% to 30% [oral], 65% to 70% [IV] as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 0 to 3 months of age: 0.13 to 0.21 &plusmn; 0.06 L/hour/kg; &gt;3 to 12 months: 0.49 &plusmn; 0.17 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;11 years of age of age: 0.54 &plusmn; 0.34 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 11 to 15 years of age: 0.48 &plusmn; 0.14 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.39 &plusmn; 0.14 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11368091\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> A famotidine suspension (8 mg/mL) is commercially available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>8 mg/mL Oral Suspension</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">An 8 mg/mL oral suspension may be made with tablets. Crush seventy 40 mg tablets in a mortar and reduce to a fine powder. Add small portions of sterile water and mix to a uniform paste. Mix while adding a 1:1 mixture of Ora-Plus and Ora-Sweet in incremental proportions to <b>almost</b> 350 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 350 mL. Label &quot;shake well.&quot; Stable for 95 days at room temperature.</p>\n    <div class=\"reference\">Dentinger PJ, Swenson CF, Anaizi NH. Stability of famotidine in an extemporaneously compounded oral liquid. <i>Am J Health Syst Pharm.</i> 2000;57(14):1340-1342.<span class=\"pubmed-id\">10918924</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169909\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Famotidine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/2 mL (2 mL): $0.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/4 mL (4 mL): $2.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $8.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Famotidine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/5 mL (50 mL): $176.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Pepcid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/5 mL (50 mL): $235.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Famotidine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $1.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $173.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $401.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pepcid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $363.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $645.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169913\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acifam (JO);</li>\n      <li>Androtin (MX);</li>\n      <li>Antiflam (UY);</li>\n      <li>Antodine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Aulzadin (HK);</li>\n      <li>Ausfam (AU);</li>\n      <li>Bestidine (KR);</li>\n      <li>Corocyd (ID);</li>\n      <li>Denufam (ID);</li>\n      <li>Durater (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Facid (ID, IN);</li>\n      <li>Facidex (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Fadin (TW, VN);</li>\n      <li>Fadine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Fadul (DE);</li>\n      <li>Famagen (KR);</li>\n      <li>Famo (BD, IL);</li>\n      <li>Famoc (SG);</li>\n      <li>Famocid (AE, BF, BJ, CI, ET, GH, GM, GN, IN, KE, KW, LR, MA, ML, MR, MU, MW, NE, NG, QA, SA, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Famodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Famodil (IT);</li>\n      <li>Famodin (RO);</li>\n      <li>Famodine (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, MY, OM, PK, QA, SA, SY, YE);</li>\n      <li>Famogal (CO);</li>\n      <li>Famogard (RU);</li>\n      <li>Famohexal (AU);</li>\n      <li>Famonerton (DE);</li>\n      <li>Famopsin (CY, TR);</li>\n      <li>Famosan (CZ, EE, HR);</li>\n      <li>Famosia (TH);</li>\n      <li>Famotaz (LK);</li>\n      <li>Famotec (AE, QA);</li>\n      <li>Famotid (BR);</li>\n      <li>Famotin (SG);</li>\n      <li>Famowal (IN);</li>\n      <li>Famox (BR, NZ, TW);</li>\n      <li>Famozol (UA);</li>\n      <li>Faradin (HK);</li>\n      <li>Farotin (KR);</li>\n      <li>Ferotine (KR);</li>\n      <li>Fibonel (CL);</li>\n      <li>Fudone (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Fuweidin (TW);</li>\n      <li>Gasafe (TW);</li>\n      <li>Gasmodin (VN);</li>\n      <li>Gaster (CN, JP, KR, TW);</li>\n      <li>Gastren (PY);</li>\n      <li>Gastridin (IT);</li>\n      <li>Gastril (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gastrium (PY);</li>\n      <li>Gastro (IL);</li>\n      <li>Gastrodomina (BF, BJ, CI, ET, GH, GM, GN, HU, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Gastrum (CO);</li>\n      <li>H2 Bloc (PH);</li>\n      <li>Hastrotyd (UA);</li>\n      <li>Hista-Bloc (PH);</li>\n      <li>Interfam (HK);</li>\n      <li>Keamotin (HK);</li>\n      <li>Kimodin (TW);</li>\n      <li>Kvamatel (UA);</li>\n      <li>Logos (ZA);</li>\n      <li>Ludex (MX);</li>\n      <li>Modin (PH);</li>\n      <li>Motiax (IT);</li>\n      <li>Motidin (HU);</li>\n      <li>Navatac (BD);</li>\n      <li>Nenvofam (VN);</li>\n      <li>Nulcerin (ES);</li>\n      <li>Nulcex (ES);</li>\n      <li>Pamacid (AU);</li>\n      <li>Pepcid (BB, BM, BS, BZ, ES, GB, GY, IE, JM, SE, SR, TT);</li>\n      <li>Pepcid AC (CH);</li>\n      <li>Pepcidac (FR);</li>\n      <li>Pepcidin (DK, FI, JO, NL, QA, SE);</li>\n      <li>Pepcidina (PT);</li>\n      <li>Pepcidine (AT, BE, CH, LU, MX, NZ, PE, VN);</li>\n      <li>Pepdif (TR);</li>\n      <li>Pepdine (BF, BJ, CI, ET, FR, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Pepfamin (TH);</li>\n      <li>Peptifam (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Peptoci (TH);</li>\n      <li>Pepzan (AU, MY, NZ);</li>\n      <li>Pharmotidine (PH);</li>\n      <li>Quamatel (HU, LV);</li>\n      <li>Quamtel (BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Rogasti (IL);</li>\n      <li>Sedanium-R (GR);</li>\n      <li>Snow (BD);</li>\n      <li>Stadin (KR);</li>\n      <li>Stomax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Supertidine (TW);</li>\n      <li>Tarpan (PY);</li>\n      <li>Tismafam (ID);</li>\n      <li>Topcid (IN);</li>\n      <li>Ulcatif (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ulcelac (AR);</li>\n      <li>Ulcenol (VE);</li>\n      <li>Ulceran (AE, BG, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, TR, YE);</li>\n      <li>Ulfadin (CO);</li>\n      <li>Ulfagel (EC);</li>\n      <li>Ulfamid (HR, HU, PL);</li>\n      <li>Ulmo (ID);</li>\n      <li>Vesmo-20 (TH);</li>\n      <li>Voker (MY);</li>\n      <li>Weimok (TW);</li>\n      <li>Winiful (TW);</li>\n      <li>Yamadin (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aanpreung P, Vanprapar N, Susiva C, Parkpreaw C, Boonyachart C. A randomized clinical trial comparing the efficacy of ranitidine and famotidine on intragastric acidity in critically ill pediatric patients. <i>J Med Assoc Thai</i>. 1998;81(3):185-189.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/9623009/pubmed\" target=\"_blank\" id=\"9623009\">9623009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Society of Anesthesiologists (ASA). Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. <i>Anesthesiology</i>. 2016;124(2):270-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/26580836/pubmed\" target=\"_blank\" id=\"26580836\">26580836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. <i>Am J Health Syst Pharm</i>. 1999;56(4):347-379.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/10690219/pubmed\" target=\"_blank\" id=\"10690219\">10690219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Behrens R, Hofbeck M, Singer H, Scharf J, Rupprecht T. Frequency of stress lesions of the upper gastrointestinal tract in paediatric patients after cardiac surgery: effects of prophylaxis. <i>Br Heart J</i>. 1994;72(2):186-189.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/7917695/pubmed\" target=\"_blank\" id=\"7917695\">7917695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canani RB, Cirillo P, Roggero P, et al, &quot;Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,&quot; <i>Pediatrics</i>, 2006, 117(5):e817-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/16651285/pubmed\" target=\"_blank\" id=\"16651285\">16651285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Courtney, TP, Shaw RW, Cedar E, et al, &quot;Excretion of Famotidine in Breast Milk,&quot; Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts. <i>Br J Clin Pharmacol</i>, 1988;26(5):639P.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/3207568/pubmed\" target=\"_blank\" id=\"3207568\">3207568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Famotidine injection [prescribing information]. New Yorl NY: Pfizer Labs; January 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guillet R, Stoll BJ, Cotten CM, et al, &quot;Association of H<sub>2</sub>-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants,&quot; <i>Pediatrics</i>, 2006, 117(2):137-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/16390920/pubmed\" target=\"_blank\" id=\"16390920\">16390920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000; 343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James LP and Kearns GL, &ldquo;Pharmacokinetics and Pharmacodynamics of Famotidine in Paediatric Patients,&rdquo; <i>Clin Pharmacokinet</i>, 1996, 31(2):103-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/8853932/pubmed\" target=\"_blank\" id=\"8853932\">8853932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James LP, Marotti T, Stowe CD, et al, &quot;Pharmacokinetics and Pharmacodynamics of Famotidine in Infants,&quot; <i>J Clin Pharmacol</i>, 1998, 38(12):1089-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/11301560/pubmed\" target=\"_blank\" id=\"11301560\">11301560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraus G, Krishna DR, Chmelarsch D, Schmid M, Klotz U. Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. <i>Clin Pharmacokinet</i>. 1990;18(1):77-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/2311331/pubmed\" target=\"_blank\" id=\"2311331\">2311331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/24327038/pubmed\" target=\"_blank\" id=\"24327038\">24327038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial.<i> Aliment Pharmacol Ther</i>. 2003;17(9):1097-1107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/12752346 /pubmed\" target=\"_blank\" id=\"12752346 \">12752346 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pepcid AC Maximum Strength tablet (famotidine) [prescribing information]. Fort Washington, PA: McNeil Consumer Pharmaceuticals Co.; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pepcid (famotidine powder for suspension) [prescribing information]. Minneapolis, MN: Perrigo; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pepcid (famotidine powder for suspension) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pepcid tablet (famotidine) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poluzzi E, Raschi E, Moretti U, et al, &ldquo;Drug-Induced Torsades de Pointes: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS),&rdquo; <i>Pharmacoepidemiol Drug Saf</i>, 2009, 18(6):512-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/19358226/pubmed\" target=\"_blank\" id=\"19358226\">19358226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16225482\"></a>Richter JE. Review article: the management of heartburn in pregnancy. <i>Aliment Pharmacol Ther</i>. 2005;22(9):749-757. doi: 10.1111/j.1365-2036.2005.02654.x<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/16225482/pubmed\" target=\"_blank\" id=\"16225482\">16225482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rudolph CD, Mazur LJ, Liptak GS, et al, &quot;Guidelines for Evaluation and Treatment of Gastroesophageal Reflux in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(Suppl 2):1-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/11525610/pubmed\" target=\"_blank\" id=\"11525610\">11525610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrin G, Passariello A, De Curtis M, et al, &quot;Ranitidine Is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns,&quot; <i>Pediatrics</i>, 2012, 129(1):40-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/22157140/pubmed\" target=\"_blank\" id=\"22157140\">22157140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treem WR, Davis PM, and Hyams JS, &ldquo;Suppression of Gastric Acid Secretion by Intravenous Administration of Famotidine in Children,&rdquo; <i>J Pediatr</i>, 1991, 118(5):812-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/ 2019939 /pubmed\" target=\"_blank\" id=\" 2019939 \"> 2019939 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van der Woude CJ, Metselaar HJ, Danese S. Management of gastrointestinal and liver diseases during pregnancy. <i>Gut</i>. 2014;63(6):1014-1023.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/24429582/pubmed\" target=\"_blank\" id=\"24429582\">24429582</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang X, Rytting E, Abdelrahman DR, Nanovskaya TN, Hankins GD, Ahmed MS. Quantitative determination of famotidine in human maternal plasma, umbilical cord plasma and urine using high-performance liquid chromatography-mass spectrometry. <i>Biomed Chromatogr</i>. 2013;27(7):866-873.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/23401067/pubmed\" target=\"_blank\" id=\"23401067\">23401067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang X, Zhan Y, Hankins GD et al. Pharmacokinetics of famotidine in pregnant women. <i>Am J Obstet Gynecol</i>. 2011;204:S72-S73.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wenning LA, Murphy MG, James LP, et al, &quot;Pharmacokinetics of Famotidine in Infants,&quot; <i>Clin Pharmacokinet</i>, 2005, 44(4):395-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-pediatric-drug-information/abstract-text/15828852/pubmed\" target=\"_blank\" id=\"15828852\">15828852</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13295 Version 224.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F169927\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F169928\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058659\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442486\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058653\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F169901\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F169887\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058663\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F169921\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058662\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7305905\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F169983\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F169907\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F169891\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820029\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299312\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F169896\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F169924\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F169898\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F169910\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50456256\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F169890\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F169906\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11368091\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F169909\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F169913\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13295|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=famotidine-drug-information\" class=\"drug drug_general\">Famotidine: Drug information</a></li><li><a href=\"topic.htm?path=famotidine-patient-drug-information\" class=\"drug drug_patient\">Famotidine: Patient drug information</a></li></ul></div></div>","javascript":null}